导师类型

硕士生导师

办公地点

6教308

职称/职务

副教授

电子邮箱

xinghong.zhao@sicau.edu.cn

研究方向

细菌耐药性控制：肽类抗生素及其精准递送系统

学术、技术组织任职/头衔

四川省特聘专家、四川省“天府峨眉计划”青年科技人才、著名传染病学国际学术期刊ACS Infectious Diseases副主编。

教育背景及工作经历

2023/04至今永利yl23411官网副教授

2021/08-2023/03 永利yl23411官网特聘副教授

2020/06–2021/08荷兰格罗宁根大学微生物与生化药学博士后

2017/08–2020/06荷兰格罗宁根大学微生物与生化药学博士

教学课程

生物技术制药、仪器分析（药）

人才培养情况

指导在读硕士生5名、本科生8名

科研项目

（近五年）

1、四川省自然科学基金面上项目，2024.11-2026.10，在研，主持

2、天府英才工程专项，2023.04-2026.03，在研，主持

3、四川省国际科技创新合作面上项目，202201-202312，结题，主持

4、永利yl23411官网引进人才科研启动项目，202108-202607，在研，主持

主要论著、

代表性论文

现已发表SCI收录论文30余篇，被Chemical reviews、Trends in Biotechnology和Nature Communications等国际著名期刊引用1400余次，H指数22。近五年以第一作者或通讯作者（含共同）在Nature Communications（2024, IF=16.6）、Advanced Science(2024, IF=14.3)、Cell Chemical Biology（2020, IF=9.039）、Advanced Materials（2024, IF=27.4）、Advanced Healthcare Materials（2024, IF=10）、International Journal of Biological Macromolecules（2024, IF=8.2）和Journal of Controlled Release（2024, IF=10.8）等专业领域权威期刊发表SCI收录论文20余篇，系统的解决了细菌耐药性控制中的多项难题。代表性论文如下：

[1]Xinghong Zhao^#,*, Xinyi Zhong^#, Shinong Yang^#, Jiarong Deng, Kai Deng, Zhengqun Huang, Yuanfeng Li, Zhongqiong Yin*, Yong Liu*, Jakob H. Viel, and Hongping Wan*. "Guiding antibiotics towards their target using bacteriophage proteins."NatureCommunications,2024, 15: 5287.（IF = 16.6，第一作者兼通讯作者）

[2] Hongping Wan^#,*, Xinyi Zhong^#, Shinong Yang^#, Jiarong Deng^#, Xu Song, Yong Liu*, Yuanfeng Li*, Zhongqiong Yin,Xinghong Zhao*. "Enhancing the Therapeutic Potential of Peptide Antibiotics Using Bacteriophage Mimicry Strategies. "Advanced Science, 2024, 2411753. (IF = 14.3，最后一位通讯作者)

[3]Xinghong Zhao, Zhibo Li, and Oscar P. Kuipers*. "Mimicry of a Non-ribosomally Produced Antimicrobial, Brevicidine, by Ribosomal Synthesis and Post-translational Modification."Cell Chemical Biology,2020, 27(10): 1262-1271.（IF = 9.039，第一作者）

[4] Xiaowen Hu, Dongdong Li, Huaping Li, Yinzi Piao*, Hongping Wan, Tieli Zhou, Mahdi Karimi,Xinghong Zhao*, Yuanfeng Li*, Linqi Shi, Yong Liu*. "Reaction-Induced Self-Assembly of Polymyxin Mitigates Cytotoxicity and Reverses Drug Resistance."Advanced Materials,2024, 2406156. (IF = 27.4，共同通讯作者)

[5] Kai Deng^#, Zhengqun Huang^#, Bo Jing, Lin Zhu, Yumei Feng, Qin Jiang, Zhiwen Xu, Hongping Wan*, andXinghong Zhao*. "Mucoadhesive chitosan-catechol as an efficient vaccine delivery system for intranasal immunization."International Journal of Biological Macromolecules,2024, 133008.（IF = 8.2，最后一位通讯作者）

[6] Yumeng Wang^#,Xinghong Zhao^#, Xingjian Zhou^#, Juqin Dai, Xiaowen Hu, Yinzi Piao, Guangyue Zu, Jian Xiao*, Keqing Shi*, Yong Liu*, Yuanfeng Li*, and Linqi Shi. "A supramolecular hydrogel dressing with antibacterial, immunoregulation, and pro-regeneration ability for biofilm-associated wound healing."Journal of Controlled Release,2024, 368:740-755.（IF = 10.8，共同第一作者）

[7] Hongping Wan^#,*, Kai Deng^#, Zhengqun Huang^#, Yunhan Yang, Bo Jing, Yumei Feng, Yuanfeng Li, Yong Liu, Mingqin Liu, andXinghong Zhao*. "Pathogen-mimicking Nanoparticles Based on Rigid Nanomaterials as an Efficient Subunit Vaccine Delivery System for Intranasal Iimmunization."Advanced Healthcare Materials,2024, 2401120.（IF = 10，最后一位通讯作者）

[8]Xinghong Zhao^#,*, Xinyi Zhong^#, Shinong Yang^#, Kai Deng, Lu Liu, Xu Song, Yuanfeng Zou, Lixia Li, Xun Zhou, Renyong Jia, Juchun Lin, Huaqiao Tang, Gang Ye, Jianqing Yang, Shan Zhao, Yifei Lang, Hongping Wan*, Zhongqiong Yin*, and Oscar P. Kuipers. "Elucidating the Mechanism of Action of the Gram-Negative-Pathogen-Selective Cyclic Antimicrobial Lipopeptide Brevicidine."Antimicrobial Agents and Chemotherapy,2023:e00010-23.（IF = 5.938，第一作者兼通讯作者）

[9]Xinghong Zhao, Zhongqiong Yin, Eefjan Breukink, Gert N. Moll, and Oscar P. Kuipers*. "An engineered double lipid II binding motifs-containing lantibiotic displays potent and selective antimicrobial activity against Enterococcus faecium."Antimicrobial Agents and Chemotherapy,2020, 64(6): e02050-19.（IF = 5.938，第一作者）

[10] Yongcheng He^#, Jiarong Deng^#, Xinyi Zhong^#, Shujun Dai, Xu Song, Yuanfeng Zou, Gang Ye, Xun Zhou, Zhongqiong Yin, Hongping Wan*,Xinghong Zhao*. "Engineered Hybrid Lantibiotic that Selectively Combats Infections Caused by Staphylococcus aureus."ACS Infectious Diseases,2024.（IF = 4，最后一位通讯作者）